You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2 expression

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2 Expression and Clinical Pathological Characteristics in

Recruiting
  • HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
  • Collect HER2 expression in prostate cancer patients
  • Jinan, Shandong, China
    Qilu hospital
Nov 17, 2023

HER2-positive Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

HER2-low Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)

Not yet recruiting
  • HER2 Low Breast Carcinoma
  • SHR-A1811 for injection
  • (no location specified)
Jun 12, 2023

Cervical Cancer Recurrent Trial in Beijing (RC48 + Tislelizumab)

Recruiting
  • Cervical Cancer Recurrent
  • RC48 + Tislelizumab
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 25, 2023

Solid Tumor Trial (Disitamab vedotin)

Not yet recruiting
  • Solid Tumor
  • Disitamab vedotin
  • (no location specified)
Jul 10, 2023

Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

Not yet recruiting
  • Non-Muscle Invasive Bladder Cancer
  • HER2
  • (no location specified)
Jul 16, 2023

Primary Breast Cancer Trial (SPECT)

Not yet recruiting
  • Primary Breast Cancer
  • (no location specified)
Jun 19, 2023

HER2, Colorectal Cancer Trial (Disitamab Vedotin Combined With Fruquintinib)

Not yet recruiting
  • HER2
  • Colorectal Cancer
  • Disitamab Vedotin Combined With Fruquintinib
  • (no location specified)
Dec 21, 2022

Breast Cancer Trial (SHR-A1811 for injection ; capecitabine)

Not yet recruiting
  • Breast Cancer
  • SHR-A1811 for injection ; capecitabine
  • (no location specified)
May 4, 2023

HER-2 Expression in Pancreatic Duct Adenocarcinoma

Completed
  • Pancreatic Adenocarcinoma
  • immunohistochemical approach
  • (no location specified)
Sep 20, 2023

Breast Cancer Female Trial in Tomsk ([99mTc]Tc-G3-(G3S)3C)

Enrolling by invitation
  • Breast Cancer Female
  • Tomsk, Russian Federation
    Olga
Jun 19, 2023

Muscle Invasive Bladder Cancer, HER2 Expression, Radiotherapy Trial in Shanghai (Disitamab Vedotin and Toripalimab)

Recruiting
  • Muscle Invasive Bladder Cancer
  • +4 more
  • Disitamab Vedotin and Toripalimab
  • Shanghai, Shanghai, China
    Renji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Jul 31, 2023

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Not yet recruiting
  • Urothelial Carcinoma
    • (no location specified)
    Jun 5, 2023

    Breast Cancer, Ovarian Cancer, Breast Tumors Trial in Dnipro, Kyiv (Axitinib)

    Enrolling by invitation
    • Breast Cancer
    • +7 more
    • Dnipro, Ukraine
    • +1 more
    Jun 17, 2023

    Breast Cancer, Neoadjuvant Therapy Trial in Wuhan (Disitamab Vedotin combined with Tislelizumab)

    Recruiting
    • Breast Cancer
    • Neoadjuvant Therapy
    • Disitamab Vedotin combined with Tislelizumab
    • Wuhan, Hubei, China
      WuhanHU
    May 16, 2023

    Metastatic Breast Cancer Trial in Zhengzhou (SHR-A1811, Pyrotinib, Bevacizumab)

    Not yet recruiting
    • Metastatic Breast Cancer
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Mar 13, 2023

    Esophageal Tumors, Gastric Tumors Malignant, Breast Cancer Trial in Stockholm ([68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2

    Recruiting
    • Esophageal Neoplasms
    • +3 more
    • [68Ga]Ga-ABY-025 PET
    • Biopsy and analysis of HER2 expression
    • Stockholm, Sweden
      Department of Radiation Physics and Nuclear Medicine, Karolinska
    Nov 25, 2022

    Triple-Negative Breast Cancer Trial in Shanghai (Trastuzumab Deruxtecan)

    Not yet recruiting
    • Triple-Negative Breast Cancer
    • Trastuzumab Deruxtecan
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jul 12, 2023

    Breast Cancer Trial in London ([18F]GE-226)

    Recruiting
    • Breast Cancer
    • [18F]GE-226
    • London, United Kingdom
      Imperial College Healthcare NHS Trust
    Jan 3, 2023

    Breast Cancer, Female Trial in Tomsk (ADAPT6-SPECT)

    Recruiting
    • Breast Cancer
    • Female
    • Tomsk, Russian Federation
      Tomsk NRMC
    Jun 7, 2022

    99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast

    Enrolling by invitation
    • Breast Cancer Female
    • 99mTc-DARPinG3 SPECT/CT
    • Tomsk, Russian Federation
      Russia Tomsk NRMC
    Jan 23, 2023

    Breast Cancer Female Trial in Tomsk (SPECT)

    Enrolling by invitation
    • Breast Cancer Female
    • Tomsk, Russian Federation
      TomskNRMC
    Jan 21, 2022

    Gastric Cancer Trial in Beijing (RC48-ADC, Herceptin, Toripalimab)

    Not yet recruiting
    • Gastric Cancer
    • Beijing, China
      Beijing Cancer Hospital
    Aug 7, 2023

    Molecular Imaging in HER2-positive Breast Cancer During

    Enrolling by invitation
    • HER2-positive Breast Cancer
    • Female
    • Tomsk, Russian Federation
    • +1 more
    Jun 7, 2022